These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18481498)

  • 21. Recombinant factor VIIa for the correction of coagulopathy before emergent craniotomy in blunt trauma patients.
    Brown CV; Foulkrod KH; Lopez D; Stokes J; Villareal J; Foarde K; Curry E; Coopwood B
    J Trauma; 2010 Feb; 68(2):348-52. PubMed ID: 20154547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7).
    Hacquard M; Durand M; Lecompte T; Boini S; Briançon S; Carteaux JP
    Eur J Cardiothorac Surg; 2011 Dec; 40(6):1320-7. PubMed ID: 21550261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center.
    Morse BC; Dente CJ; Hodgman EI; Shaz BH; Nicholas JM; Wyrzykowski AD; Salomone JP; Vercruysse GA; Rozycki GS; Feliciano DV
    Am Surg; 2011 Aug; 77(8):1043-9. PubMed ID: 21944521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry.
    Phillips LE; McLintock C; Pollock W; Gatt S; Popham P; Jankelowitz G; Ogle R; Cameron PA;
    Anesth Analg; 2009 Dec; 109(6):1908-15. PubMed ID: 19923520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion.
    Spinella PC; Perkins JG; McLaughlin DF; Niles SE; Grathwohl KW; Beekley AC; Salinas J; Mehta S; Wade CE; Holcomb JB
    J Trauma; 2008 Feb; 64(2):286-93; discussion 293-4. PubMed ID: 18301188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.
    Guzzetta NA; Russell IA; Williams GD
    Anesth Analg; 2012 Aug; 115(2):364-78. PubMed ID: 22652310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
    Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
    Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage.
    Diringer MN; Ferran JM; Broderick J; Davis S; Mayer SA; Steiner T; Brun NC; Skolnick BE; Christensen MC
    Cerebrovasc Dis; 2007; 24(2-3):219-25. PubMed ID: 17630481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of recombinant factor VIIa for adjunctive hemorrhage control in trauma and surgical patients.
    Benharash P; Bongard F; Putnam B
    Am Surg; 2005 Sep; 71(9):776-80. PubMed ID: 16468517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Administration off label of recombinant factor-VIIa (rFVIIa) to patients with blunt or penetrating brain injury without coagulopathy.
    Zaaroor M; Soustiel JF; Brenner B; Bar-Lavie Y; Martinowitz U; Levi L
    Acta Neurochir (Wien); 2008 Jul; 150(7):663-8. PubMed ID: 18473114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE).
    Gruppo RA; Kessler CM; Neufeld EJ; Cooper DL
    Haemophilia; 2013 Jul; 19(4):524-32. PubMed ID: 23551918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant activated factor VII use in the emergency department.
    Fishman PE; Drumheller BC; Dubon ME; Slesinger TL
    Emerg Med J; 2008 Oct; 25(10):625-30. PubMed ID: 18843055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.
    Boffard KD; Riou B; Warren B; Choong PI; Rizoli S; Rossaint R; Axelsen M; Kluger Y;
    J Trauma; 2005 Jul; 59(1):8-15; discussion 15-8. PubMed ID: 16096533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with recombinant activated factor VII in a series of 45 trauma patients.
    Felfernig M;
    J R Army Med Corps; 2007 Mar; 153(1):32-9. PubMed ID: 17575875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of the off-label use of recombinant activated factor VII in a developing country tertiary care center.
    El Accaoui R; Isma'eel H; Khalil PB; Taher A
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):647-50. PubMed ID: 17102651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry.
    Cameron P; Phillips L; Balogh Z; Joseph A; Pearce A; Parr M; Jankelowitz G
    Injury; 2007 Sep; 38(9):1030-8. PubMed ID: 17706654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation of an off-label recombinant factor VIIa protocol for patients with critical bleeding at an academic medical center.
    Bain J; Lewis D; Bernard A; Hatton K; Reda H; Flynn J
    J Thromb Thrombolysis; 2014 Nov; 38(4):447-52. PubMed ID: 24980752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Recombinant factor VIIa for the treatment of exsanguinating trauma patients: a matched-pair analysis from the Trauma Registry of the German Society for Trauma Surgery].
    Wafaisade A; Lefering R; Maegele M; Helm P; Braun M; Paffrath T; Bouillon B;
    Unfallchirurg; 2013 Jun; 116(6):524-30. PubMed ID: 22699315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia.
    Morfini M; Bjerre J
    Haemophilia; 2011 Nov; 17(6):860-6. PubMed ID: 21371194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.